Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

We designed a single-arm, open label phase II study to determine the efficacy and toxicity of the combination of pazopanib with CapeOx (capecitabine and oxaliplatin) in metastatic /recurrent advanced gastric cancer (AGC) patients. Previously untreated AGC patients received capecitabine (850 mg/m(2)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Kim, Seung Tae, Lee, Jeeyun, Lee, Su Jin, Park, Se Hoon, Jung, Sin-Ho, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Joon Oh
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029686/
https://ncbi.nlm.nih.gov/pubmed/27003363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8175
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados